Gilead Sciences breaks ground on new manufacturing and technical development site in US
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
The U.S. FDA issued a Form 483 with five observations
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The three-day expo will feature an expansive exhibition showcasing MSMEs, startups, research institutions, future innovation pavilions, state showcases, and government initiatives
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Subscribe To Our Newsletter & Stay Updated